Chemomab Therapeutics:Nebokitug类风湿关节炎2期临床试验预计2027年上半年启动,2028年上半年公布数据

美股速递
Aug 19

Chemomab Therapeutics Ltd.近日宣布,其核心候选药物Nebokitug针对类风湿关节炎(RA)的2期临床试验预计将于2027年上半年正式启动。这项备受关注的研究有望在2028年上半年公布关键数据。

这一时间表的确定,标志着公司在推进Nebokitug的临床开发进程中迈出了重要一步。作为一款备受期待的在研药物,Nebokitug的2期试验结果将为其后续的临床路径提供关键参考。市场对这款药物的研发进展保持着高度关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10